Imaging of Prostate Cancer Recurrence with MRI

Andrei S Purysko, M.D.
Abdominal Imaging Section & Nuclear Radiology Department
• Research support from Invivo Corp.
1. Discuss the utility of MRI in the evaluation of suspected PCa recurrence
2. Illustrate the expected post-treatment changes and patterns of PCa recurrence on MRI after most common treatment modalities
**PCa Recurrence**

- Occurs in 10-53% of patients, depending on risk group and treatment modality
- Typically detected by elevation in PSA levels after treatment, which can precede symptoms by months to years

<table>
<thead>
<tr>
<th>Treatment modality</th>
<th>Biochemical (BCR) criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radical Prostatectomy (RP)</td>
<td>Two consecutive PSA levels &gt; 0.2 ng/mL</td>
</tr>
<tr>
<td>Radiation therapy (RT)</td>
<td>PSA level ≥ 2.0 ng/mL above nadir</td>
</tr>
<tr>
<td>Cryotherapy (Cryo)</td>
<td>No consensus, but some use same as RT</td>
</tr>
</tbody>
</table>
Pattern of BCR may suggest recurrence location

<table>
<thead>
<tr>
<th></th>
<th>Local recurrence</th>
<th>Distant metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCR time</td>
<td>Late (&gt;24 months)</td>
<td>Early (&lt;24 months)</td>
</tr>
<tr>
<td>PSA velocity</td>
<td>Slow</td>
<td>Fast</td>
</tr>
<tr>
<td>PSA doubling time (PSADT)</td>
<td>&gt;6 months</td>
<td>&lt;6 months</td>
</tr>
</tbody>
</table>

Since tumor burden does not always correlate with serum PSA, imaging is often performed to distinguish local recurrence from distant metastases and to assist in treatment planning.
MRI is considered the most accurate method for detection of local PCa recurrence, even in early stages (PSA <1.0 ng/mL)

MRI Technique and interpretation: No consensus

- PI-RADS does not address PCa recurrence
  - Should not give a PI-RADS score
- 1.5 or 3T, with or without ERC
- Multiparametric: T2 and T1-WI, DWI, DCE
- Evidence available suggests that DCE has greater importance in this setting than on initial detection
Radical Prostatectomy (RP)
MRI after RP – Expected Findings

• Bladder descends towards the rectum
• **Fibrotic tissue** develops in the prostatectomy bed and vesicoureteral anastomosis
  - T2-WI: fibrotic tissue shows dark signal
  - DWI/ADC: no restricted diffusion
  - DCE: delayed and progressive enhancement
MRI after RP – Expected Findings

- Bladder descends towards the rectum
- **Fibrotic tissue** develops in the prostatectomy bed and vesicoureteral anastomosis
  - T2-WI: fibrotic tissue shows dark signal
  - DWI/ADC: no restricted diffusion
  - DCE: delayed and progressive enhancement
MRI after RP – Recurrence

• Most common locations: perianastomotic, retrovesical, or in the SV bed

• MRI features:
  - T2-WI: nodular lesion with intermediate SI
  - DWI/ADC: restricted diffusion
  - DCE: early enhancement +/- wash-out

78 y.o man s/p RP for GS 4+3 stage T2b PCa presents with BCR (PSA: 2.0ng/mL)
MRI after RP – Recurrence

- Most commonly locations: perianastomotic, retrovesical, or in the SV bed
- MRI features:
  - T2-WI: nodular lesion with intermediate SI
  - DWI/ADC: restricted diffusion
  - DCE: early enhancement +/- wash-out

77 y.o man s/p RP for GS 3+4 stage T2b PCa presents with BCR (PSA: 2.6ng/mL)
MRI after RP – Recurrence

- Most commonly locations: perianastomotic, retrovesical, or in the SV bed
- MRI features:
  - T2-WI: nodular lesion with intermediate SI
  - DWI/ADC: restricted diffusion
  - DCE: early enhancement +/- wash-out

59 y.o man s/p RP for GS 4+3 stage T3a PCa presents with BCR (PSA: 1.14ng/mL)
MRI after RP – Recurrence

- Most commonly locations: perianastomotic, retrovesical, or in the SV bed

- MRI features:
  - T2-WI: nodular lesion with intermediate SI
  - DWI/ADC: restricted diffusion
  - DCE: early enhancement +/- wash-out

68 y.o. man s/p RP and RT for GS 4+5 stage T3b PCa who presented with BCR after stopping ADT (PSA 3.9ng/ml)
MRI after RP – Residual Disease

- PSA should be undetectable 12 weeks after RP
- Failure to decrease PSA is caused by residual PCa or normal prostatic tissue
- Positive surgical margin is an indicator of residual disease

PCa GS 5 + 4 on TRUS bx and PSA 13.4 ng/mL.
MRI after RP – Residual Disease

- PSA should be undetectable 12 weeks after RP
- Failure to decrease PSA is caused by residual PCa or normal prostatic tissue
- Positive surgical margin is an indicator of residual disease

Post-op PSA: 140ng/mL
MRI after RP – Residual Prostate

- Residual prostatic tissue and SV occurs in 10-50% of cases
- Should have SI similar to that of normal prostatic tissue

73 y.o. man s/p RP for a GS 3+4 stage T2b PCa with persistently elated but stable post-op PSA (1.27ng/mL). TRUS revealed a small hypoechoic mass at the base of the bladder concerning for recurrence.
MRI after RP – Other sites

- MRI can also help detect lymph node involvement in the pelvis and lower retroperitoneum as well as pelvic bone metastases
  - **Lymph node metastasis:** >1cm (short axis), heterogeneous signal, irregular borders
  - **Bone metastasis:** Low T1-WI SI, restricted diffusion and early enhancement

59 y.o. man s/p RP for GS 4+3 stage T3a PCa with persistently elevated post-op PSA 1.8ng/mL
Radiation Therapy (RT)
MRI after RT—Expected findings

- Prostate and SV become atrophic
- T2-WI: diffuse low SI; there may be loss of zonal anatomy
- DWI/ADC: no restricted diffusion
- DCE: Decreased and delayed enhancement except for urethra and residual BPH
MRI after RT – Recurrence

- Local recurrence occurs in the site of original disease
- DCE assumes a key role since T2-WI and DWI/ADC may be affected by post-treatment changes and susceptibility artifacts
  - T2-WI: nodular lesion with iso/hypointense SI
  - DWI/ADC: restricted diffusion
  - DCE: early enhancement +/- wash-out

72 y.o. man s/p Brachytherapy for GS 3+4 PCa detected by TRUS biopsy of left sided sextants, presents with BCR (PSA 6.1 ng/mL)
MRI after RT—Recurrence

- Local recurrence occurs in the site of original disease
- DCE assumes a key role since T2-WI and DWI/ADC may be affected by post-treatment changes and susceptibility artifacts
  - T2-WI: nodular lesion with iso/hypointense SI
  - DWI/ADC: restricted diffusion
  - DCE: early enhancement +/- wash-out
MRI after RT—Recurrence

- Local recurrence occurs in the site of original disease
- DCE assumes a key role since T2-WI and DWI/ADC may be affected by post-treatment changes and susceptibility artifacts

75 y.o man s/p **brachytherapy** for GS 4+3 detected by TRUS in right sided sextants, presents with BCR (PSA 3.5ng/mL)
MRI after RT – Recurrence

- After EBRT, recurrence has similar features seen with Brachytherapy.
- DCE also plays an important role since post treatment changes can hamper assessment on DWI/ADC.

68 y.o. man s/p EBRT for 4+3 PCa presents with BRC (PSA 0.7ng/ml)
MRI after RT—Recurrence

- After EBRT, recurrence has similar features seen with Brachytherapy
- DCE also plays an important role since post treatment changes can hamper assessment on DWI/ADC

58 y.o. man s/p EBRT for 4+3 PCa presents with BRC (PSA 1.1 ng/ml)
MRI after RT – Complications

- MRI can also be helpful in the evaluation of complications after RT

72 y.o. man S/p EBRT for PCa presents with undetectable PSA but with dysuria, recurrent UTI and pelvic pain. MRI shows a large rectovesical fistula.
Cryotherapy
MRI after Cryotherapy – Expected findings

- Can be used to treat whole gland or as a focal therapy
- Often used to treat low risk disease or local recurrence after RT
- Fibrotic tissue develops in the ablation bed distorting the anatomical structures
  - T2-WI: irregularly shaped fibrotic tissue with low SI
  - DWI/ADC: no restricted diffusion
  - DCE: delayed and progressive enhancement
MRI after Cryotherapy – Expected findings

- Can be used to treat whole gland or as a focal therapy
- Often used to treat low risk disease or local recurrence after RT
- Fibrotic tissue develops in the ablation bed distorting the anatomical structures
  - T2-WI: irregularly shaped fibrotic tissue with low SI
  - DWI/ADC: no restricted diffusion
  - DCE: delayed and progressive enhancement
MRI after Cryotherapy – Recurrence

- PSA is a less reliable method for evaluation of recurrence, especially when cryoablation is used for focal therapy
- Routine biopsies may be required
  - T2-WI: nodular lesion with low/intermediate SI
  - DWI/ADC: restricted diffusion
  - DCE: early enhancement +/- wash-out

64 y.o. man with h/o GS 3+3 Pca initially treated with SBRT followed by whole gland cryo for BCR, now with rising PSA (0.8ng/mL)
MRI after Cryotherapy – Recurrence

- Pre-treatment images can assist in the detection of recurrence

77 y.o. man with h/o GS 3+4 Pca initially treated with SBRT followed by whole gland cryo for BCR, now with rising PSA (3.37ng/mL)
Teaching Points

- PCa recurrence is a common problem, especially in patients with high risk disease.
- Mp-MRI is an important tool for evaluation of residual/recurrent disease in patients with persistently elevated or rising PSA after therapy.
- PCa recurrence is often identified in the site of original disease.
- DCE has more important role than on initial diagnosis, due to expected post-therapy changes and commonly encountered artifacts that affect T2-WI and DWI.
Thank you!